MIRAPEX helps your PD patients maintain everyday activities²

Initial monotherapy with MIRAPEX offers effective control of early PD^1,4

• Initiating therapy with MIRAPEX helps control symptoms and facilitates a levodopa-saving strategy to reduce the risk of motor complications^1,4 Learn more
• When used as initial monotherapy, MIRAPEX provides significant improvements in UPDRS ADL scores, demonstrating enhanced patient functioning in as few as 3 weeks⁸ Learn more

Combination therapy with MIRAPEX offers improved functioning in moderate to advanced PD³

• MIRAPEX, in combination with levodopa, provides more "on" time—with better quality functioning³ Learn more

MIRAPEX helps control symptoms to enhance patient functioning^2,3

• Initial MIRAPEX helps patients maintain their everyday activities over 4 years¹ Learn more
• MIRAPEX, in combination with levodopa, provides more "on" time—with better quality functioning^2,3 Learn more
• MIRAPEX, in combination with levodopa, significantly improved resting tremor vs placebo⁷ Learn more

Delays and reduces motor complications

• MIRAPEX delays and reduces the onset of major motor complications vs levodopa¹ Learn more

MIRAPEX is well tolerated and offers convenient dosing

• MIRAPEX has no predicted P450 drug interactions^{6, 23, 24} Learn more

  Urinary excretion is the major route of MIRAPEX elimination, with >90% of dose recovered in urine. Dosage should be adjusted in patients with renal impairment

• MIRAPEX is generally well tolerated in patients with early and advanced disease Learn more
• MIRAPEX quickly titrates to an effective dose and offers a flexible dosing schedule Learn more

Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including MIRAPEX, to treat Parkinson's disease.